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To compare the performance of VIA and Pap smear tests as screening tools in cervical carcinoma detection 
in women.  
Methods 
The prospective and retrospective study was conducted on 198 women. Cervical smears were collected 
with Ayres’s spatula. Acetic acid was used and the results were categorized as VIA positive and VIA 
negative. The Pap smear was reported according to the Bethesda system 2001. Cervical biopsy was done 
for all the cases. 
Results 
VIA was positive in 47.47% of the cases and Pap smear was positive in 39.89% of the cases. Among 198 
cases, 61 (30, 8%) cases had cervical carcinoma. When we compared VIA and Pap smear tests, 94 cases 
were positive to VIA, and 61cases were confirmed positive with Pap smear. The sensitivity and specificity 
for VIA were 88.5% and 84.68%, respectively. The sensitivity and specificity for Pap smear were 80.45% 
and 91.89%, respectively. The sensitivity of VIA was higher than that of Pap smear. However, the 
specificity of VIA was low as compared to Pap smear. 
Conclusion 
VIA is a cost effective test and could be alternatively used with Pap smear in screening of cervical 
carcinoma but the Papanicolaou test is the most effective test for early detection of cervical carcinoma. 
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INTRODUCTION 
Cervical carcinoma is uncontrolled growth that 
starts in the uterine cervical epithelium cells 
caused by several factors include Human 
Papilloma Virus (HPV).[1] The normal cells of 
the cervix gradually develop pre-cancerous 
changes that turn into cancer. There are 2 
main types of cervical carcinoma: squamous 
cell carcinoma and adenocarcinoma. The 
squamous cells cover the surface of the 
exocervix. The second type of cervical 
carcinoma is adenocarcinoma which develops 
from mucus-producing glands cells of 
endocervix.[1] 
Cervical cancer rates have fallen in most of the 
developed countries, probably as a result of 
screening and treatment programs. In contrast, 
the rates in most developing countries have 
risen or remained unchanged. In 2008 there 
were 529,000 new cases of cervical carcinoma, 




and more than 270,000 women die every year; 
85% of them were from developing countries, 
especially in Africa where an estimated 53,000 
women die of the cervical cancer every year. [2] 
Overall, 77% of new cases of cervical carcinoma 
and 88% of deaths occur in the developing 
world, where 95% of women have never been 
screened for this cancer.[3] 
In sub-Saharan Africa, 34.8 new cases of 
cervical carcinoma are diagnosed per 100, 000 
women annually, and 22.5 per 100,000 women 
die from the cervical carcinoma. These 
statistics were compared with 6.6 and 2.5 per 
100,000 women, respectively, in North 
America. The drastic differences can be 
explained by lack of access to effective 
screening and services that facilitate early 
detection and treatment.[2]  
Cervical carcinoma ranks as the second most 
frequent cancer among women in Rwanda. In 
2008, Rwanda had 34.5 cases of cervical 
carcinoma and 25.4 deaths attributable to 
cervical cancer per 100,000 women.[4] Cervical 
carcinoma is rare in women under 30 years old 
and it is most common in women over 40 
years, with the greatest number of deaths 
usually occurring in women aged between 50 
and 60 years. Rwanda has a population of 3.90 
million women over 15 years who are at risk of 
developing cervical carcinoma. Current 
estimates indicate that every year, 1304 women 
are diagnosed with cervical carcinoma and 921 
die from the cervical cancer.[5] However, in 
Eastern Africa, about 33.6% of women in the 
general population are estimated to harbor 
cervical HPV infection at a given time,[6] and 
the HPV 16 or 18 types contribution to invasive 
cervical carcinoma ranged to 56.4% in 1994 
and 91.5%  in 2003.[7,8]  
Cytology-based screening, however, has not 
proven to be as successful in low-resource 
settings of the developing world. Lack of trained 
pathologists and technicians and a deficiency 
of laboratories have contributed to that failure. 
Furthermore, Pap smears can miss cervical 
carcinoma, especially in low-quality 
laboratories; consequently they must be 
repeated every year to increase the chance of 
early detection.[9] 
Epidemiological studies have consistently 
shown that the most important determinants of 
HPV infection in women are: the number of 
sexual partners, the age of initiation of sexual 
activity, and the sexual behavior of the male 
partner. Cervical carcinoma is preventable and 
curable if detected at early stage; but, in order 
to minimize cervical screening barriers in low-
resource settings, strategies should be socially 
and culturally appropriate and health workers 
should be knowledgeable about correct 
procedures.[10]  Although, the education about 
screening plays a vital role in cervical 
carcinoma prevention, most of Rwandese 
women are not aware about the symptoms and 
mode of transmission of cervical carcinoma.[3] 
Papanicolaou (PAP) smear is a simple, safe, 
non-invasive and effective method for detection 
of pre-cancerous, cancerous and non-
cancerous changes in the cervix and vagina. 
The use of acetic acid during visual 
examination of the cervix, termed visual 
inspection with acetic acid (VIA), has been 
advocated as an alternative screening method 
to PAP smears in developing countries.[11] In 
this regards, the aim of this study was to 
compare VIA test and Pap smear test in order 
of assess their role in cervical carcinoma 
screening. 
METHODS 
This study was prospective and retrospective, 
comparative study carried out at Butare 
University Teaching Hospital (BUTH/CHUB), in 
Rwanda, southern province, District of Huye, in 
the departments of Gynecology and Anatomical 
Pathology from April 2011 to August 2014. 
Women aged 20 years and above who attended 
the gynecology department at CHUB with 
complaints of vaginal discharge, pelvic pain, 
post-coital bleeding were enrolled in this study. 
Women who had undergone hysterectomy or 
treatment for cervical pre-cancer or cancer, 
women with visible growth of cancer on the 
cervix, who are in menstrual period and 
pregnant women were excluded from the study. 
A total number of 198 women diagnosed or 
screened for cervical cancer at CHUB were 
included in this study. In this study, 
prospective and retrospective methods have 
been used. In prospective method, 20 samples 
were collected. In retrospective method, 178 
samples were collected using both files in 
Gynecology and Anatomical Pathology 
department. 
 





During the data collection, the information on 
names, age, sex, the residential area, marital 
status and phone numbers, clinical 
pathological features of cervical carcinoma 
pelvic pain, vaginal bleeding, vagina discharge 
and grade of the tumor were obtained through 
a pre-designed structured data collection form. 
The cervix was painted with 3–4% acetic acid 
and observed for aceto-white lesions (positive 
VIA) in gynecology department. Both negative 
and positive VIA results were collected by 
Ayres’s spatula for Pap smear test. Samples 
were fixed in 95% ethyl alcohol and taken to 
the Pathology Department for interpretation. 
The Pap smear was reported according to the 
Bethesda system 2001. Patients with positive 
Pap smear results were again called back for 
biopsy. Biopsy served as the reference standard 
for cervical carcinoma diagnosis. Samples were 
analyzed using all steps of cytology and 
histopathology techniques. Cytology technique 
was Papanicolaou staining and histopathology 
technique was tissue processing. Samples were 
interpreted by a pathologist on light microscope 
(x400 magnification). 
Data analysis 
Data were registered on a paper data sheet and 
later analyzed using Microsoft Excel. Categorical 
variables were presented as frequency (n), 
percentage (%) in tables. 
Ethical considerations 
An authorization letter was given by INES 
administration. This study was carried out at 
CHUB after approval by the ethical committee 
of CHUB. The names of the patients were not 
recorded for ethical reason. All personal 
information was kept confidentially and only 
used for the study purposes.  
 
RESULTS 
In this study, the performance of VIA and Pap smear tests were analyzed and compared for a total of 198 
women. The main symptoms as reason of testing were: the vaginal bleeding with 94 (47.47%) cases 
followed by pelvic pain with 65 (32.82%) cases and vaginal discharge with 39 (19.69%) cases. 
Table 1. The distribution of patients screened for cervical carcinoma according to age. 
Age range Number of 
participants 
Percentage 
21-30 years 17 8.6 
31-40 years 49 24.8 
41-50 years 64 32.3 
51-60 years 45 22.7 
61-70 years 23 11.6 
Total 198 100 
 
In table 1, the age range 31-40 years and age range 41-50 years show a high number of women screened 
for cervical carcinoma. 
 
 
























21-30 17 4 2.02 13 6.56 
31-40 49 11 5.55 38 19.19 
41-50 64 29 14.64 35 17.67 
51-60 45 38 19.19 7 3.53 
61-70 23 12 6.06 11 5.55 
Total 198 94 47.47 104 52.52 
. 
In table 2, VIA positive tests were 47.47% overall. In the age range 51-60, 38(19.19%) acetowhite positives 
has been tested; VIA negative results were 52.52% overall. 
























21-30 2 1.01 0 0 0 0 2 1.01 
31-40 5 2.52 1 0.5 4 2.02 10 5.05 
41-50 3 1.51 1 0.5 7 3.53 11 5.55 
51-60 6 3.03 2 1.01 30 15.15 38 19.19 
61-70 4 2.02 2 1.01 12 6.06 18 9.09 
Total 20 10.09 6 3.03 53 26.76 79 39.89 
LSIL: Low Squamous Intraepithelial Lesions, HSIL: High Squamous Intraepithelial Lesions, SCC: 
Squamous Cell Carcinoma. 









































21-30 12 6.06 2 1.01 1 0.5 15 7.57 
31-40 33 16.66 4 2.02 2 1.01 39 19.69 
41-50 23 11.61 5 2.52 25 12.62 53 26.76 
51-60 0 0 4 2.02 3 1.51 7 3.53 
61-70 0 0 4 2.02 1 0.5 5 2.52 
Total 68 34.34 19 9.59 32 16.16 119 60.1 
 
Table 4 shows that 119 (60.1%) of women have been diagnosed as negative with Pap smear tests, Atypical 
Squamous Cells of Undifferentiated Significance (ASCUS) were 19 (9.59%) cases and 32 (16.16%) cases 
were benign cellular changes. 






In table 5, among 94 cases that were positive to VIA, 61 were confirmed positive with Pap smear, 18 of 
those that were negative to VIA were confirmed positive to Pap smear. 














  Pap smear positive Pap smear negative Total 
VIA positive 61 33 94 
VIA negative 18 86 104 
Total 79 119 198 
Biopsy test result Number of cases % of the total sample 
Chronic cervicitis 111 56.06 
Mild dysplasia 20 10.1 
Moderate dysplasia 2 1.01 
Severe dysplasia 4 2.02 
SCC 53 26.76 
Adenocarcinoma 8 4.04 
Total 198 100 




Table 6 shows biopsy results as a confirmation test. Mild dysplasia, moderate dysplasia, severe dysplasia 
and SCC were considered as positive for neoplasia. Final diagnostic by histopathology was taken as gold 
standard. 
Out of 198 cases, 111 (56.06%) were diagnosed as chronic cervicitis, 20 (10.1%) as mild dysplasia (CIN I), 2 
(1.01%) as moderate dysplasia (CIN II), 4 (2.02%) as severe dysplasia, 53 (26.76%) as squamous cells 
carcinoma and 8 (4.04%) as adenocarcinoma. Hence, biopsy test showed 87 (43.9%) positive cases. 
Table 7. Comparison of VIA and Pap smear tests to biopsy examination 
 Tests  Positive biopsy Negative biopsy Total 
Positive VIA 77 17 94 
Negative VIA 10 94 104 
Positive Pap smear  70 9 79 
Negative Pap smear 17 102 119 
Table 7 compares VIA and Pap smear tests to biopsy test. It presents true positives and true negatives, 
false positives and false negatives. For VIA test, the true positives were 77 for the presence of cervical 
carcinoma; 10 cases were false negatives; true negatives were 94 cases and false positive were 17 cases. 
For Pap smear, 70 cases out of 198 cases were true positive for the presence of cervical carcinoma; 17 
cases were false negatives; true negatives were 102 cases and false positive were 9 cases. 
Table 8 presents sensitivity, specificity, positive predictive value, negative predictive value and diagnostic 
accuracy of VIA and Pap smear tests 










TP: True positive, FP: False positive, TN: True negative, FN: False negative 
As shown in table 8, the sensitivity of VIA was 88.5% and that of Pap smear 80.45%. The specificity of VIA 
was 84.68%and that of Pap smear was 91.89%. The positive predictive value of VIA was 81.91% whereas 
that of Pap smear was 88.6%. The negative predictive value of VIA was 90.38% whereas that of Pap smear 
was 85.71%. The diagnostic accuracy of VIA was 86.36% whereas that of Pap smear was 86.86%.
 
Parameters VIA estimate Pap smear estimate 
Sensitivity = TP/TP+FN 77 /87 × 100 = 
88.5% 
70 /87 × 100 = 80.45% 
Specificity = TN/TN+FP 94 / 111× 100 = 
84.68% 
102 /111 × 100 = 91.89% 
Positive predictive value = TP/TP+FP 77/94× 100 = 
81.91% 
70 /79 × 100 = 88.6% 
Negative predictive value = 
TN/TN+FN 
94 / 104× 100 = 
90.38% 
102 /119 × 100 = 85.71% 






70+102/198 = 86.86% 





The present study was conducted to compare 
the role of Acetic acid and Pap smear test as 
cervical carcinoma screening tools for women 
who attended CHUB. The age range of women 
involved in this study was 20-70 years. This 
age range is similar to that used by Khan S et 
al in 2007, where in their study, this screening 
method was studied in the age range of 25 to 
65 years and also the age range of our study is 
related to that used by the American Cancer 
Society in 2013, which recommended all 
women to begin cervical carcinoma screening at 
age 21 to 65 years old.[1, 12] The age group 
ranging 51-60 years old was at high risk of 
developing the cervical carcinoma because this 
age group is the menopause period. 
In this study, vaginal bleeding was the most 
common presenting complaint for cervical 
carcinoma with 63% of the cases. The second 
common complaint was pelvic pain in 23% and 
the last was vaginal discharge with 14% in case 
of cervical carcinoma. These complaints for 
cervical carcinoma are found in similar studies. 
In the study at Mysore Medical College and 
Research Institute by Suman K, in 2012, 
vaginal discharge was reported as the most 
common presenting complaint (77.14%) 
followed by pelvic pain (43%).[13] Also similar 
complaints were found in Sudan, where 
Dhabhadel et al, in 2008, reported pelvic pain 
as the most common complaint (56.8%) 
followed by vaginal discharge (27.43%).[14] 
In present study, 10.1% cases of LSIL, and 
3.03 % cases of HSIL were reported. In 
contrast, Lozowiski, et al., in 1982, found that 
LSIL were 28.3% of cases and HSIL 70% of 
cases. In our study SCC cases (26.76%) are 
higher than SCC cases reported by Lozowiski et 
al. (1. 5%).[15] This large difference may be due 
to individual variations in the interpretation of 
Squamous Intra-epithelial Lesions. 
In the present study, the proportion of women 
who were screened positive with VIA was 
47.47% and with Pap smear it was 39.89%. 
Our findings were higher than those observed 
in other studies in India by Divya H et al., in 
2011, which showed 12% cases of VIA positive 
while positive Pap smear were 11.7% cases. 
Singh K et al., in 2010 showed 16. 2% cases of 
positive VIA and 5.2% cases of positive Pap 
smear.[16, 17] The reason for higher positivity 
rates of VIA and Pap smear tests in the present 
study may be that the current study was 
conducted in a referral hospital. It was done on 
hospital based population in which high risk 
cases were screened. 
In the present study, the sensitivity of VIA was 
higher (88.5%) than that of Pap smear 
(80.45%). This result is similar to that found in 
the study conducted by Vadehra K, et al., in 
2006 where sensitivity of VIA was higher 
(96.4%) than that of Pap smear (71.4%).[18] 
In our study, the specificity of VIA was lower at 
(84.68%) as compared to Pap smear (91.89%). 
Our results relate to the findings reported by 
Garg P. in 2011, where the specificity of VIA 
was 82% and that of Pap smear was 91.1%. 
[19] 
In the present study, the positive predictive 
value of Pap smear was higher (88.6%) than 
that of VIA (81.91%). The present results are 
similar to that found in University of 
Zimbabwe/JHPIEGO cancer project (1999) 
where the positive predictive value of Pap 
smear was elevated (40.7%) than that of VIA 
(22.7%).[20] 
The negative predictive value for VIA was high 
than that of Pap smear 90.38% and 85.71% 
respectively. Garg P, in 2011, has found the 
equivalent rate where negative predictive value 
for VIA was 99. 7% whereas Pap smears was 
98.7%. [19] 
In the current study, the diagnostic accuracy of 
VIA was (86.36%) whereas that of Pap smear 
was (86.86%). These results are similar to that 
found by Albert et al., in 2012, where the 
diagnostic accuracy of VIA was 98.6% whereas 
for Pap smears it was 99.4%.[21] 
The specificity of VIA for cervical carcinoma 
screening would guide to over-treatment of 
non-neoplastic lesions. VIA is of particular 
interest in CHUB because it only requires 
equipment locally obtainable, and can be 
competently performed by non-physicians with 
prior training. The Pap smear stills the best 
method for screening of cervical carcinoma 
because of its high specificity. In addition, the 
sensitivity of VIA is higher than that of Pap 
smear test.  Thus, VIA and Pap smear test 
could be alternatively used in the screening of 
cervical carcinoma. Further study is needed to 
compare the new cervical cancer screening test 




called HPV-DNA test with the tests used in the 
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